N-(2-(乙酰氧基)乙基)-乙酰胺 | 16180-96-4

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: N-(2-(乙酰氧基)乙基)-乙酰胺
• 中文别名: 2-乙酰氨基乙基乙酸酯
• 英文名称: N-<2-(acetyloxy)ethyl>acetamide
• 英文别名: 2-acetamidoethanol acetate；1-acetoxy-2-acetylamino-ethane；1-Acetoxy-2-acetylamino-aethan；N-(2-Acetoxy-aethyl)-acetamid；O.N-Diacetyl-colamin；(β-Acetamino-aethyl)-acetat；2-Acetamidoethyl acetate
• CAS: 16180-96-4
• 化学式: C₆H₁₁NO₃
• mdl: MFCD00026208
• 分子量: 145.158
• InChiKey: SKPWGBMKZNVXFF-UHFFFAOYSA-N

物化性质

• 沸点：
  103 °C(Press: 0.049 Torr)
• 密度：
  1.059±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.6
• 重原子数：
  10
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.666
• 拓扑面积：
  55.4
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2924199090

SDS

---

SECTION 1: Identification of the substance/mixture and of the company/undertaking
Product identifiers
Product name : N-(2-ACETOXYETHYL)ACETAMIDE
REACH No. : A registration number is not available for this substance as the substance
or its uses are exempted from registration, the annual tonnage does not
require a registration or the registration is envisaged for a later
registration deadline.
CAS-No. : 16180-96-4

---

SECTION 2: Hazards identification
Classification of the substance or mixture
Classification according to Regulation (EC) No 1272/2008
Eye irritation (Category 2), H319
For the full text of the H-Statements mentioned in this Section, see Section 16.
Classification according to EU Directives 67/548/EEC or 1999/45/EC
Xi Irritant R36
For the full text of the R-phrases mentioned in this Section, see Section 16.
Label elements
Labelling according Regulation (EC) No 1272/2008
Pictogram
Signal word Warning
Hazard statement(s)
Causes serious eye irritation.
Precautionary statement(s)
P305 + P351 + P338 IF IN EYES: Rinse cautiously with water for several minutes. Remove
contact lenses, if present and easy to do. Continue rinsing.
Supplemental Hazard none
Statements
Other hazards - none

---

SECTION 3: Composition/information on ingredients
Substances
Formula : C6H11NO3
Molecular Weight : 145,16 g/mol
CAS-No. : 16180-96-4
Hazardous ingredients according to Regulation (EC) No 1272/2008
Component Classification Concentration
N-(2-ACETOXYETHYL)ACETAMIDE
CAS-No. 16180-96-4 Eye Irrit. 2; H319 <= 100 %
For the full text of the H-Statements and R-Phrases mentioned in this Section, see Section 16

---

SECTION 4: First aid measures
Description of first aid measures
General advice
Consult a physician. Show this safety data sheet to the doctor in attendance.
If inhaled
If breathed in, move person into fresh air. If not breathing, give artificial respiration. Consult a physician.
In case of skin contact
Wash off with soap and plenty of water. Consult a physician.
In case of eye contact
Rinse thoroughly with plenty of water for at least 15 minutes and consult a physician.
If swallowed
Never give anything by mouth to an unconscious person. Rinse mouth with water. Consult a physician.
Most important symptoms and effects, both acute and delayed
The most important known symptoms and effects are described in the labelling (see section 2.2) and/or in
section 11
Indication of any immediate medical attention and special treatment needed
no data available

---

SECTION 5: Firefighting measures
Extinguishing media
Suitable extinguishing media
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide.
Special hazards arising from the substance or mixture
Carbon oxides, nitrogen oxides (NOx)
Advice for firefighters
Wear self contained breathing apparatus for fire fighting if necessary.
Further information
no data available

---

SECTION 6: Accidental release measures
Personal precautions, protective equipment and emergency procedures
Use personal protective equipment. Avoid dust formation. Avoid breathing vapours, mist or gas. Ensure
adequate ventilation. Avoid breathing dust.
For personal protection see section 8.
Environmental precautions
Do not let product enter drains.
Methods and materials for containment and cleaning up
Pick up and arrange disposal without creating dust. Sweep up and shovel. Keep in suitable, closed
containers for disposal.
Reference to other sections
For disposal see section 13.

---

SECTION 7: Handling and storage
Precautions for safe handling
Avoid contact with skin and eyes. Avoid formation of dust and aerosols.
Provide appropriate exhaust ventilation at places where dust is formed.
For precautions see section 2.2.
Conditions for safe storage, including any incompatibilities
Store in cool place. Keep container tightly closed in a dry and well-ventilated place.
Specific end use(s)
Apart from the uses mentioned in section 1.2 no other specific uses are stipulated

---

SECTION 8: Exposure controls/personal protection
Control parameters
Components with workplace control parameters
Exposure controls
Appropriate engineering controls
Handle in accordance with good industrial hygiene and safety practice. Wash hands before breaks and
at the end of workday.
Personal protective equipment
Eye/face protection
Safety glasses with side-shields conforming to EN166 Use equipment for eye protection tested
and approved under appropriate government standards such as NIOSH (US) or EN 166(EU).
Skin protection
Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique
(without touching glove's outer surface) to avoid skin contact with this product. Dispose of
contaminated gloves after use in accordance with applicable laws and good laboratory practices.
Wash and dry hands.
The selected protective gloves have to satisfy the specifications of EU Directive 89/686/EEC and
the standard EN 374 derived from it.
Body Protection
impervious clothing, The type of protective equipment must be selected according to the
concentration and amount of the dangerous substance at the specific workplace.
Respiratory protection
For nuisance exposures use type P95 (US) or type P1 (EU EN 143) particle respirator.For higher
level protection use type OV/AG/P99 (US) or type ABEK-P2 (EU EN 143) respirator cartridges.
Use respirators and components tested and approved under appropriate government standards
such as NIOSH (US) or CEN (EU).
Control of environmental exposure
Do not let product enter drains.

---

SECTION 9: Physical and chemical properties
Information on basic physical and chemical properties
a) Appearance Form: solid
b) Odour no data available
c) Odour Threshold no data available
d) pH no data available
e) Melting point/freezing no data available
point
f) Initial boiling point and no data available
boiling range
g) Flash point no data available
h) Evapouration rate no data available
i) Flammability (solid, gas) no data available
j) Upper/lower no data available
flammability or
explosive limits
k) Vapour pressure no data available
l) Vapour density no data available
m) Relative density no data available
n) Water solubility no data available
o) Partition coefficient: n- log Pow: -0,454
octanol/water
p) Auto-ignition no data available
temperature
q) Decomposition no data available
temperature
r) Viscosity no data available
s) Explosive properties no data available
t) Oxidizing properties no data available
Other safety information
no data available

---

SECTION 10: Stability and reactivity
Reactivity
no data available
Chemical stability
Stable under recommended storage conditions.
Possibility of hazardous reactions
no data available
Conditions to avoid
no data available
Incompatible materials
Strong oxidizing agents
Hazardous decomposition products
Other decomposition products - no data available
In the event of fire: see section 5

---

SECTION 11: Toxicological information
Information on toxicological effects
Acute toxicity
no data available
Skin corrosion/irritation
no data available
Serious eye damage/eye irritation
no data available
Respiratory or skin sensitisation
no data available
Germ cell mutagenicity
no data available
Carcinogenicity
IARC: No component of this product present at levels greater than or equal to 0.1% is identified as
probable, possible or confirmed human carcinogen by IARC.
Reproductive toxicity
no data available
Specific target organ toxicity - single exposure
no data available
Specific target organ toxicity - repeated exposure
no data available
Aspiration hazard
no data available
Additional Information
RTECS: Not available
To the best of our knowledge, the chemical, physical, and toxicological properties have not been
thoroughly investigated.

---

SECTION 12: Ecological information
Toxicity
no data available
Persistence and degradability
no data available
Bioaccumulative potential
no data available
Mobility in soil
no data available
Results of PBT and vPvB assessment
PBT/vPvB assessment not available as chemical safety assessment not required/not conducted
Other adverse effects
no data available

---

SECTION 13: Disposal considerations
Waste treatment methods
Product
Offer surplus and non-recyclable solutions to a licensed disposal company. Dissolve or mix the material
with a combustible solvent and burn in a chemical incinerator equipped with an afterburner and scrubber.
Contaminated packaging
Dispose of as unused product.

---

SECTION 14: Transport information
UN number
ADR/RID: - IMDG: - IATA: -
UN proper shipping name
ADR/RID: Not dangerous goods
IMDG: Not dangerous goods
IATA: Not dangerous goods
Transport hazard class(es)
ADR/RID: - IMDG: - IATA: -
Packaging group
ADR/RID: - IMDG: - IATA: -
Environmental hazards
ADR/RID: no IMDG Marine pollutant: no IATA: no
Special precautions for user
no data available

---

SECTION 15: Regulatory information
This safety datasheet complies with the requirements of Regulation (EC) No. 1907/2006.
Safety, health and environmental regulations/legislation specific for the substance or mixture
no data available
Chemical Safety Assessment

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  N-(2-(乙酰氧基)乙基)-乙酰胺 在 五氯化磷 作用下， 以 四氯化碳 为溶剂， 生成 1-Acetoxy-2-(dichloracetamido)aethan
  参考文献：
  名称：

  五氯化磷与酰胺，特别是2-乙酰氨基-2-脱氧醛二氢吡喃葡萄糖的反应

  摘要：

  摘要通过五氯化磷的作用，将2-乙酰氨基-2-脱氧醛二氢吡喃葡萄糖多乙酸酯转化为2-四氯亚乙基氨基衍生物，反式-2-乙酰氨基-1-乙酸体系的反应比顺式更快。1-乙酰氨基-吡喃葡萄糖基多乙酸酯提供了1-四氯亚乙基氨基衍生物和2-O-三氯乙酰基-β-D-吡喃葡萄糖基氯。除其他产物外，还观察到后者，是由β-D-吡喃葡萄糖基叠氮化物四乙酸酯与五氯化磷的反应引起的。在乙酰胺基环己烷及其2-乙酰氧基衍生物上进行的类似反应得到二氯乙酰胺基，三氯乙酰胺基和四氯乙叉基氨基衍生物。同样，1-乙酰氨基-2-乙酰氧基乙烷得到1-二氯乙酰氨基衍生物。

  DOI：

  10.1016/s0008-6215(00)87007-x
• 作为产物：
  描述：

  N-<2-Chlor-ethyl>-diacetyl-amin 在 silver nitrate 作用下， 以 乙腈 为溶剂， 生成 N-(2-(乙酰氧基)乙基)-乙酰胺
  参考文献：
  名称：

  Heteronuclear stabilized carbonium ions. II. N-Aroyl- and aryl-2-oxazolinium cations. Intermediates in a new class of neighboring group reactions

  摘要：

  DOI：

  10.1021/jo00943a004
• 作为试剂：
  描述：

  、 氨 、 乙酰胺 、 2-氯乙酸乙酯 在 盐酸 、 乙酸乙酯 、 magnesium sulfate 、 N-(2-(乙酰氧基)乙基)-乙酰胺 作用下， 以 氨基钠 为溶剂， 25.0~140.0 ℃ 、35.55 kPa 条件下， 反应 8.0h， 以to obtain an aqueous solution of pH 5的产率得到N-(2-(乙酰氧基)乙基)-乙酰胺
  参考文献：
  名称：

  Production process of N-substituted amide compounds

  摘要：

  在维持强碱物质处于悬浮状态的同时，通过引发起始酰胺化合物（如饱和或不饱和的脂肪族或芳香族羧酸酰胺）与卤代化合物（如烷基卤化物）之间的反应，高产地生产出一种N-取代酰胺化合物。

  公开号：

  US04835312A1

文献信息

• A novel series of N-(1-aminoalkylidene)carboximidamides as potential hypoglycemia agents
  作者：Henry J. Breslin、Michael J. Kukla、Robert W. Tuman、Mary C. Rebarchak、Charles R. Bowden

  DOI：10.1021/jm00063a009

  日期：1993.5

  Nitrogen heterocyclic carboximidamides, such as linogliride, 1a, have been shown to possess significant hypoglycemic activity and have shown clinical efficacy as potential antidiabetic agents. We evaluated the biological significance of the heterocyclic ring A of general structure 1, which has always been maintained in this class of compounds, by preparing acyclic compounds of general structure 2.

  氮杂环羧酰亚胺类化合物（如linogliride，1a）已显示出显着的降血糖活性，并已显示出作为潜在抗糖尿病药的临床疗效。我们通过制备通用结构2的无环化合物，评估了通用结构1的杂环A的生物学意义。该结构在此类化合物中一直保持着。初步的体内生物学测试，即大鼠的葡萄糖耐量测试，指出，制备的许多特定的无环羧酰亚胺化合物6a-kk具有显着的降血糖活性，通常与我们的模型化合物1a所示的活性相当，在某些情况下更好。这些结果表明1的杂环A对于这类化合物的降血糖活性不是必需的。
• COMPOSITIONS AND METHODS FOR THE TREATMENT OF RESPIRATORY DISORDERS
  申请人：Kandula Mahesh

  公开号：US20150133407A1

  公开（公告）日：2015-05-14

  The invention relates to the compounds of formula I or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, and methods for the treatment of respiratory disorders may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of viscid or excessive mucus, cough, inflammation, redness in sore throat, infection in the throat, sore throat, abnormal mucus secretion, impaired mucus transport, allergic rhinitis, asthma, COPD, respiratory muscular disorders and pain in acute sore throat.

  本发明涉及公式I的化合物或其药用可接受的盐，以及它们的聚合物、溶剂化物、对映体、立体异构体和水合物。包含有效量的公式I化合物的药物组合物，以及用于治疗呼吸系统疾病的方法，可以口服、颊部、直肠、局部、经皮、经粘膜、静脉、非肠道给药、糖浆或注射剂的形式制备。此类组合物可用于治疗粘性或过量粘液、咳嗽、喉咙痛的红肿、喉咙感染、喉咙痛、异常粘液分泌、粘液运输受损、过敏性鼻炎、哮喘、慢性阻塞性肺病（COPD）、呼吸肌疾病和急性喉咙痛的疼痛。
• [EN] COMPOSITIONS AND METHODS FOR THE TREATMENT OF FUNGAL INFECTIONS<br/>[FR] COMPOSITIONS ET PROCÉDÉS DE TRAITEMENT D'INFECTIONS FONGIQUES
  申请人：CELLIX BIO PRIVATE LTD

  公开号：WO2018096497A1

  公开（公告）日：2018-05-31

  The invention relates to the compounds or its pharmaceutical acceptable polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, formula II, formula III, formula IV, formula V, formula VI, formula VII, formula VIII, formula IX or Formula X and, the methods for the treatment of fungal infections may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, lozenge, spray, intravenous, oral solution, buccal mucosal layer tablet, parenteral administration, syrup, or injection. Such compositions may be used to treatment of fungal infections.

  该发明涉及化合物或其药用可接受的多型体、溶剂合物、对映体、立体异构体及其水合物。包括有效量的I式、II式、III式、IV式、V式、VI式、VII式、VIII式、IX式或X式化合物的药物组合物，以及用于治疗真菌感染的方法可以制备为口服、颊部、直肠、局部、经皮、经粘膜、含片、喷雾、静脉注射、口服溶液、颊粘膜层片剂、肠外给药、糖浆或注射剂。这些组合物可用于治疗真菌感染。
• PROCESS FOR STRAIGHTENING KERATIN FIBRES WITH A HEATING MEANS AND DENATURING AGENTS
  申请人：Philippe Michel

  公开号：US20100028280A1

  公开（公告）日：2010-02-04

  The invention relates to a process for straightening keratin fibres, comprising: (i) a step in which a straightening composition containing at least two denaturing agents is applied to the keratin fibres, (ii) a step in which the temperature of the keratin fibres is raised, using a heating means, to a temperature of between 110 and 250° C.

  该发明涉及一种直发角蛋白纤维的拉直过程，包括：(i)将至少两种变性剂含有的拉直组合物涂抹到角蛋白纤维上的步骤，(ii)使用加热装置将角蛋白纤维的温度升高至110至250°C的步骤。
• COMPOSITIONS AND METHODS FOR THE TREATMENT OF MUCOSITIS
  申请人：Kandula Mahesh

  公开号：US20150307446A1

  公开（公告）日：2015-10-29

  The invention relates to the compounds of formula I or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, and methods for the treatment of mucositis may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of mucus diseases related to painful inflammation and ulceration of the digestive tract lining and in the mouth.

  该发明涉及公式I的化合物或其药用可接受盐，以及其多晶型、溶剂合物、对映体、立体异构体和水合物。包括有效量的公式I化合物的药物组合物，以及用于治疗粘膜炎的方法可以制备为口服、颊内、直肠、局部、经皮、经粘膜、静脉、肠道给药、糖浆或注射剂。这种组合物可用于治疗与消化道内膜疼痛性炎症和溃疡相关的黏膜疾病。